Global Health Ventures Expects Completion of European Clinical Trials for X-Excite in the Fourth Quarter of 2010

VANCOUVER, BRITISH COLUMBIA--(Marketwire - August 10, 2010) - Global Health Ventures Inc. (OTCBB: GLHV) (the “Company”), a specialty pharmaceutical company hereby provides update on the development of its lead life style drug “X-Excite” designed for male sexual enhancement.

The final formulation of the drug has been completed. Similarly, the protocol for the clinical trials has been completed. The Company has contracted the regulatory management and trials monitoring to the European Contract Research Organization (CRO). The CRO has been in regular contact with the European Regulatory bodies (EMEA). The filling dossier is 90% complete. The Company is only required to provide drug stability study under normal temperature and under heat for at least one month. The Company has initiated this process and shall complete it by the middle of September 2010. At that time, the medical dossier will be supplied to EMEA for approval. The approval process will take approximately one month to 45 days. As expected, the trials shall be completed in the fourth quarter of 2010.

ABOUT GLOBAL HEALTH VENTURES - Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company’s lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. The Company also uses the same technology to deliver a vast number of other FDA approved drugs where they are needed to act rapidly. These include, stress relief, sleeping disorders, pain killers, anti-allergy, heart medication and addiction replacement.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company’s filings (10K) with the Securities and Exchange Commission.